Kohle F, Dalakas MC, Lehmann HC (2023) Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy? Ther Adv Neurol Disord 16:17562864221137128

Article  PubMed  PubMed Central  Google Scholar 

Collins MP, Hadden RD (2017) The nonsystemic vasculitic neuropathies. Nat Rev Neurol 13:302–316

Article  PubMed  Google Scholar 

Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, Léger JM, Notermans NC, Pollard JD, Said G, Sobue G, Vrancken AF, Kissel JT (2010) Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 15:176–184

Article  PubMed  Google Scholar 

Schneider C, Wassermann MK, Fink GR, Lehmann HC (2022) Single-center experience of induction therapy in non-systemic vasculitic neuropathy. Neurol Res Pract 4:32

Article  PubMed  PubMed Central  Google Scholar 

Üçeyler N, Geng A, Reiners K, Toyka KV, Sommer C (2015) Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol 262:2092–2100

Article  PubMed  Google Scholar 

Kleyweg RP, Van Der Meché FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14:1103–1109

Article  CAS  PubMed  Google Scholar 

Prineas J (1970) Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl 44:1–72

Article  CAS  PubMed  Google Scholar 

Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O’Brien PC, Grina LA, Palumbo PJ, Swanson CJ (1980) Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 8:590–596

Article  CAS  PubMed  Google Scholar 

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780

Article  PubMed  Google Scholar 

Schneider C, Wunderlich G, Bleistein J, Fink GR, Deckert M, Brunn A, Lehmann HC (2017) Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. J Neurol Neurosurg Psychiatry 88:756–760

Article  PubMed  Google Scholar 

Hofmann K, Clauder A-K, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. https://doi.org/10.3389/fimmu.2018.00835

Article  PubMed  PubMed Central  Google Scholar 

Catron DM, Rusch LK, Hataye J, Itano AA, Jenkins MK (2006) CD4+ T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells. J Exp Med 203:1045–1054

Article  CAS  PubMed  PubMed Central  Google Scholar 

García Nores GD, Ly CL, Cuzzone DA, Kataru RP, Hespe GE, Torrisi JS, Huang JJ, Gardenier JC, Savetsky IL, Nitti MD, Yu JZ, Rehal S, Mehrara BJ (2018) CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9:1970

Article  PubMed  PubMed Central  Google Scholar 

Takahashi M, Koike H, Ikeda S, Kawagashira Y, Iijima M, Hashizume A, Katsuno M, Sobue G (2017) Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurol Neuroimmunol Neuroinflamm 4:e407

Article  PubMed  PubMed Central  Google Scholar 

Margoni M, Preziosa P, Filippi M, Rocca MA (2022) Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol 269:1316–1334

Article  CAS  PubMed  Google Scholar 

Witt AM, Kodal LS, Pedersen BS, Lund EL, Dysgaard T (2023) Misinterpretation of non-systemic vasculitic neuropathy results in delayed treatment. Ugeskr Laeger 185(18):V10220665

PubMed  Google Scholar 

Lima K, Tavee J, Dua A (2021) Combination rituximab and intravenous immunoglobulin for treatment of refractory vasculitic neuropathy: a case series. Rheumatology 60:4884–4887

Article  PubMed  Google Scholar 

Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2022) Rituximab for the treatment of multiple sclerosis: a review. J Neurol 269:159–183

Article  CAS  PubMed  Google Scholar 

Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A (2019) Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 266:57–67

Article  CAS  PubMed  Google Scholar 

Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141:135–148

Article  CAS  PubMed  Google Scholar 

Perumal JS, Kister I, Howard J, Herbert J (2015) Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e61

Article  PubMed  PubMed Central  Google Scholar 

Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D (2015) Cryoglobulinemia Vasculitis. Am J Med 128:950–955

Article  PubMed  Google Scholar